𝛼SK or Searchbullish
MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726
On May 27, 2026, MetaVia, Inc. (MTVA) announced the presentation of new Phase 1 data for DA-1726, the company's oxyntomodulin analog targeting...
What is covered in the Full Insight:
- Introduction
- Recent Phase 1 Data Overview
- Safety Profile of DA-1726
- Financial and Valuation Metrics
- Future Outlook and Upcoming Catalysts
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-172628 May 2026
x